Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 96.01M P/E - EPS this Y 61.10% Ern Qtrly Grth -
Income -30.12M Forward P/E -152.00 EPS next Y -8.60% 50D Avg Chg -6.00%
Sales 17.05M PEG 0.06 EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 2.41 EPS next 5Y -25.00% 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 1.44 Shares Outstanding 79.94M 52W Low Chg 176.00%
Insider Own 8.54% ROA -35.23% Shares Float 1.09B Beta 0.82
Inst Own 5.33% ROE -171.94% Shares Shorted/Prior 179.22K/267.19K Price 1.52
Gross Margin 64.55% Profit Margin -176.67% Avg. Volume 439,077 Target Price 9.83
Oper. Margin -107.05% Earnings Date Nov 4 Volume 179,098 Change -3.18%
About BioLineRx Ltd.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd. News
06:30 AM BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
11/20/24 BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
11/05/24 BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
10/16/24 BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
09/17/24 BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
08/20/24 BLRX: On Track for 60% Formulary Placement
08/15/24 BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
08/08/24 BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
06/10/24 BLRX: First Quarter 2024 Results
06/05/24 Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
05/30/24 BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
05/28/24 BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
05/24/24 BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
05/22/24 BioLineRx to Report First Quarter 2024 Results on May 28, 2024
05/17/24 BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
05/06/24 BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
04/17/24 BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
04/10/24 BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
04/01/24 BioLineRx Announces $6 Million Registered Direct Offering
03/27/24 BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript
BLRX Chatroom

User Image Factsmachine Posted - 53 minutes from now

$BLRX adding more here.. pay-tience. You all lack it . We were at .70 pre market … over reaction.

User Image xoxoxoxo1 Posted - 38 minutes from now

$BLRX let’s get to .10 cents. Why not?! FDA approval and a penny stock. Totally makes sense

User Image Bakhmutbull2 Posted - 23 minutes from now

$BLRX Those long short funds and hedge funds own it through and through. I took my marbles and 12k loss and bought some more bitcoin. Good luck

User Image gargoyl Posted - 6 seconds from now

$BLRX HPS was originally formed as a division of Highbridge Capital Management within J.P. Morgan Asset Management and known as Highbridge Principal Strategies. Morgan Stanley (JPM grandson owns 197,000 shares of BLRX) Black Rock (who bought out Kreos Capital )is buying out Highbridge , which already bought out Gamida whose parent company is Ayrmid LTD who just scooped up rights to APHEXDA .. can’t make this stuff up. …. Ask chatGBT

User Image PHILMYWALLET Posted - 10 minutes ago

$BLRX don't listen to pumpers on here. It's the same ones that have been on here for years trying to convince gullible folks to buy this Israeli trash. Don't listen to them

User Image Lstreak Posted - 22 minutes ago

$BLRX Well CEO and crew managed to raise money to have their salaries paid for for the next few years and screw shareholders again.

User Image BLRXlongRIPorYOLO Posted - 24 minutes ago

$BLRX wow my short yesterday really paid off. Thanks Phil you're the best.

User Image Kensei Posted - 25 minutes ago

$BLRX im holding my part. I will not sell at this point.

User Image JJToni Posted - 25 minutes ago

$BLRX company has now 50M+ in hands and revenue coming from 2 fronts: Gloria & Gamida with big focus now on PDAC & rest of pipeline. BTW PDAC expected completion date is mid 2025..

User Image JrNannies Posted - 33 minutes ago

$BLRX if sell let it burn that's what they want. No appreciation for shareholders

User Image DiaJay Posted - 34 minutes ago

$BLRX I don’t see how it recovers?

User Image JrNannies Posted - 41 minutes ago

$BLRX please everyone sell

User Image Limey42 Posted - 59 minutes ago

$BLRX ouch. Going to take some monumental news to turn this ship around!

User Image HitstheGreen Posted - 1 hour ago

$BLRX

User Image Humperdink Posted - 1 hour ago

$BLRX

User Image Harold_the_Hedge Posted - 1 hour ago

$BLRX and highbridge involved again, same as $gmdaq. Sell and stay away, there is nothing left of interest here. Just my humble advice. Walk away proud

User Image Humperdink Posted - 1 hour ago

$BLRX

User Image LockMan Posted - 1 hour ago

$BLRX I think this is a drastic over-reaction. I blocked the dumb negative posters. Just adds a distraction to the overall picture. I said earlier, I am disappointed in this company as I have been a shareholder from the beginning, and it has been my biggest investment. Sure I hoped to make money. But I also had/have hopes for all those that NEED the product, which is why I originally invested. I am not giving up hope. Just wait for what happens.

User Image swarty Posted - 1 hour ago

$BLRX I still believe this drug will change the world. MM was always a step with PDAC being the prize. They had an ambitious plan to fund the PDAC through aggressive sales and it didn't work. It's never easy to admit a mistake and move on but they have and now the realignment is happening. I sold a large chunk of my holdings earlier this year when it became evident the plan wasn't going to work. But I held a small chunk to ride through this and I will buy back in to a large position eventually. None of this is easy - second guessing is noise - what are you doing to achieve the end game. They are taking the steps needed and as many great companies do - they will learn from their mistakes. This drug will change the world of cancer treatment. I won't go bear or bull on this - just hopeful. In the end, we WANT this company to succeed. Anyone who has lost a loved one to glioblastoma, ovarian, prostate, or pancreatic cancer understands.

User Image LockMan Posted - 1 hour ago

$BLRX The agreement enables significant reduction in BioLineRx's operational expenses and debt, and allows the company to focus on development activities in areas of high unmet need in oncology and rare diseases. Additionally, BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC

User Image LockMan Posted - 1 hour ago

$BLRX They will still be makin royalties, but with no expense. Plus the upfront money: BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. In exchange, BioLineRx will receive a $10 million upfront payment and is eligible to receive up to an additional $87 million of potential commercial milestones, plus royalties ranging from 18% to 23% on net sales of APHEXDA.

User Image Reese81012 Posted - 1 hour ago

$BLRX got out of this a long time ago was hoping for the best for longs smh 🤦🏾‍♂️

User Image timnim Posted - 1 hour ago

$BLRX I’ve lost more than 50k in this bet. I am out now.

User Image Humperdink Posted - 1 hour ago

$BLRX buying here...

User Image Jabed206 Posted - 1 hour ago

$BLRX Dying company it seems

User Image gargoyl Posted - 1 hour ago

$BLRX so J Loveland opens an account today to share his riveting 🧐 news .. suspect , What’s bigger at play , that these guys are paid ..

User Image TwongStocks Posted - 1 hour ago

$BLRX Here is the amendment to the loan with Kreos. https://www.sec.gov/Archives/edgar/data/1498403/000117891324003792/exhibit_10-2.htm It appears that most of the money from their deal with Ayrmid is going to go towards loan repayment. They received $10m upfront from Ayrmid. As well as $9m from the equity agreement. $19m. BLRX must make a $10m partial loan prepayment. They must also make a $6.5m payment in lieu of the revenue based fee owed to Kreos. So $16.5m must be paid right off the bat. Which eats up most of the money from the Ayrmid deal. Starting Dec 1, BLRX must begin repaying the outstanding loan balance. Schedule B of the filing has the payment amounts. Initial loan balance is $13.8m. Final payment is Dec 1, 2027.

User Image gargoyl Posted - 1 hour ago

$BLRX a little ditty from a gold miner who was the first to say “don’t throw the baby out with the bath water” . He went on to adjust his sluice to let rocks out and collect the nuggets. The News on 3QT Earnings must be such that they want in lower now. Reverse think 🤔 what they portray. Average in , they are. Who you think picked up 5M shares today. Not retail!! Long the 🦋

User Image johnsoriaknows Posted - 1 hour ago

$BLRX this is dead now. They have nothing to show except a tittle cash which will disappear with new clinical research. It's like starting from zero with a management incapable of growing shareholder value. Expect R/S after R/S and a bunch of raises going forward

User Image Humperdink Posted - 2 hours ago

$BLRX just remember, oversold levels are a great buying opportunity here. Average down as a bounce will slingshot back over $1.00

Analyst Ratings
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 29, 24
HC Wainwright & Co. Buy Apr 17, 24
HC Wainwright & Co. Buy Mar 26, 24
HC Wainwright & Co. Buy Feb 29, 24
HC Wainwright & Co. Buy Nov 20, 23
HC Wainwright & Co. Buy Sep 15, 23
HC Wainwright & Co. Buy Aug 31, 23
Oppenheimer Outperform May 25, 23